Targeted Therapy for Preeclampsia

Babies born on time...
Welcome
Home Preeclampsia Technology Intellectual property Management News Contact

Advanced Prenatal Therapeutics (APT) is developing a novel

therapeutic device for treating preeclampsia by specifically removing

harmful substances from the mother’s blood.

There are currently no other therapies available to specifically treat preeclampsia. In managing preeclampsia, the main objective is the health and survival of the mother. Premature induction of delivery, regardless of gestational age, remains the only treatment option. Our targeted therapy for preeclampsia is a simple procedure in which disease-causing factors in the mother's blood are specifically removed with APT's Targeted Apheresis Cartridge for Preeclampsia (TAC-PE), while the blood components that are natural and vital are preserved. APT's mission is to develop an effective treatment that will safely prolong pregnancy, allowing babies more time to develop in the womb. Treatment with the TAC-PE will potentially extend the duration of pregnancy, thereby reducing the risk of lifelong disabilities in babies resulting from prematurity and IUGR.
Preeclampsia affects 5-8% of pregnancies, approximately 300,000 women in the United States every year. In the US, approximately 10,500 babies die due to preeclampsia each year, and an estimated 500,000 worldwide. Preeclampsia is a leading cause of maternal illness and death. It accounts for 20% of maternal deaths, and doubles the future risk of cardiovascular and cerebrovascular diseases. Preeclampsia is a major cause of prematurity and intrauterine growth restriction (IUGR), which lead to lifelong challenges such as cardiovascular disease, learning disorders, cerebral palsy, epilepsy, blindness, and deafness. The only way to “cure” preeclampsia is to deliver the baby and remove the placenta, regardless of gestational age.
Preeclampsia Facts
Copyright © 2013     Advanced Prenatal Therapeutics, Inc  Terms of Use Privacy Policy
Images courtesy of Tom Clare (left) and David Castillo Dominici (center) via FreeDigitalPhotos.net
Home